Designation of Amikacin Sulfate as an Orphan Drug - Novotech (Australia)

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves to regulate the quality and safety of therapeutic goods. The Act was introduced to address the need for a cohesive and effective framework to ensure the safety, efficacy, and quality of therapeutic products, including medicines, medical devices, and blood products. One specific problem the Act aimed to address was the regulation of orphan drugs, which are designed for rare diseases or conditions that affect a small number of people. The designation of Amikacin Sulfate as an orphan drug for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis patients aged six years and older, is an example of the Act’s application in providing targeted treatments for rare conditions. This designation was made by Dr. Anthony Gill, the Delegate of the Secretary, under subregulation 16J(2) of the Therapeutic Goods Regulations 1990, with the policy objective of facilitating access to orphan drugs for patients in need.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration within the Department of Health, applies to the regulation of therapeutic goods in Australia. This legislation encompasses a broad spectrum of products including medicines, medical devices, blood and blood components, tissues, and in vitro diagnostic products. The Act applies to both individuals and entities involved in the supply, importation, advertising, and sponsorship of these goods. Its jurisdiction extends across the Commonwealth, ensuring a unified regulatory approach to therapeutic goods nationwide. Notably, the Act includes specific exclusions and thresholds that determine the level of regulatory oversight required, such as over-the-counter medicines versus prescription-only drugs. The application and enforcement of the Act can be further refined through subordinate instruments like the Therapeutic Goods Regulations 1990, which provide detailed provisions and specific criteria for various aspects of the therapeutic goods market. This legislative framework ensures that therapeutic goods available in Australia meet safety, quality, and efficacy standards, protecting public health while facilitating access to necessary medical treatments.

Key Provisions

The Therapeutic Goods Act 1989, as amended by the Therapeutic Goods (Orphan Drugs—Amikacin Sulfate) Determination 2015, designates Amikacin Sulfate as an orphan drug (section 16J(2) of the Therapeutic Goods Regulations 1990). This designation is specifically for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. The form of Amikacin Sulfate designated for this indication is a suspension for inhalation. This legislative action aims to encourage the development of treatments for rare and neglected diseases by providing incentives to pharmaceutical companies. The obligations imposed on the parties involved by this designation are primarily on the sponsor, Novotech (Australia) Pty Limited, as the entity responsible for the development and potential marketing of Amikacin Sulfate for this specific indication. As a designated orphan drug, Novotech is entitled to various benefits, including priority assessment by the Therapeutic Goods Administration (TGA) and potential financial incentives. The TGA is also required to expedite the review and approval process for Amikacin Sulfate for the specified indication to ensure timely access for patients with cystic fibrosis. Failure to comply with the provisions of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in both civil and criminal consequences. Section 34 of the Act outlines the penalties for manufacturing or supplying therapeutic goods that do not comply with the legislative requirements. Civil penalties can include fines of up to $1,650,000 for corporations and $330,000 for individuals, as well as potential criminal charges. For criminal offences, the maximum penalty for individuals is a fine of up to $165,000 or imprisonment for up to 12 months, or both, while corporations can face fines of up to $8,250,000. These stringent penalties underscore the importance of adherence to the regulatory framework governing therapeutic goods in Australia.